Malignant effusions in advanced ovarian carcinoma : Chemotherapy resistance and surgical treatment of stage IV disease
Metadata
Show metadataAppears in the following Collection
Abstract
List of papers. Papers I-IV are removed from the thesis due to copyright restrictions.Paper I Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B. Expression and clinical role of antiapoptotic proteins of the Bag, Heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. Int J Gynecol Pathol 2009;28:211-221. doi:10.1097/PGP.0b013e31818b0f5e
Paper II Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 2010;41:794-804. doi:10.1016/j.humpath.2009.09.017
Paper III Elstrand MB, Stavnes HT, Tropé CG, Davidson B. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol 2012;43:529-535. doi:10.1016/j.humpath.2011.05.022
Paper IV Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20-year perspective. Acta Obstet Gynecol Scand 2012;91:308-317. doi:10.1111/j.1600-0412.2011.01316.x
Paper V Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? NOTICE: this is the author’s version of a work that was accepted for publication in Eur J Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in: Eur J Cancer. 2012 Feb 28. [Epub ahead of print] doi:10.1016/j.ejca.2012.01.031